206 related articles for article (PubMed ID: 8695042)
1. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats.
Bubser M; Tzschentke T; Hauber W
J Neural Transm Gen Sect; 1995; 101(1-3):115-26. PubMed ID: 8695042
[TBL] [Abstract][Full Text] [Related]
2. Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats.
Bubser M; Keseberg U; Notz PK; Schmidt WJ
Eur J Pharmacol; 1992 Dec; 229(1):75-82. PubMed ID: 1361915
[TBL] [Abstract][Full Text] [Related]
3. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
Hauber W; Andersen R
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
[TBL] [Abstract][Full Text] [Related]
4. The NMDA antagonist, dizocilpine, enhances cocaine reinforcement without influencing mesoaccumbens dopamine transmission.
Pierce RC; Meil WM; Kalivas PW
Psychopharmacology (Berl); 1997 Sep; 133(2):188-95. PubMed ID: 9342786
[TBL] [Abstract][Full Text] [Related]
5. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization.
Tzschentke TM; Schmidt WJ
Behav Brain Res; 1997 Mar; 84(1-2):99-107. PubMed ID: 9079776
[TBL] [Abstract][Full Text] [Related]
6. Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens.
Mathé JM; Nomikos GG; Schilström B; Svensson TH
J Neurosci Res; 1998 Mar; 51(5):583-92. PubMed ID: 9512002
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the mesolimbic dopamine system by glutamate: role of NMDA receptors.
Kretschmer BD
J Neurochem; 1999 Aug; 73(2):839-48. PubMed ID: 10428083
[TBL] [Abstract][Full Text] [Related]
8. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Bibbiani F; Oh JD; Kielaite A; Collins MA; Smith C; Chase TN
Exp Neurol; 2005 Dec; 196(2):422-9. PubMed ID: 16203001
[TBL] [Abstract][Full Text] [Related]
9. Dizocilpine infusion has a different effect in the development of morphine and cocaine sensitization: behavioral and neurochemical aspects.
Scheggi S; Mangiavacchi S; Masi F; Gambarana C; Tagliamonte A; De Montis MG
Neuroscience; 2002; 109(2):267-74. PubMed ID: 11801363
[TBL] [Abstract][Full Text] [Related]
10. N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4- isoxazoleproprionate (AMPA) glutamate-receptor antagonists have different interactions with the discriminative stimuli of abused drugs.
Jackson A; Brown G; Stephens DN
Psychopharmacology (Berl); 1996 Dec; 128(3):320-7. PubMed ID: 8972552
[TBL] [Abstract][Full Text] [Related]
11. Stress activation of mesocorticolimbic dopamine neurons: effects of a glycine/NMDA receptor antagonist.
Morrow BA; Clark WA; Roth RH
Eur J Pharmacol; 1993 Jul; 238(2-3):255-62. PubMed ID: 8405096
[TBL] [Abstract][Full Text] [Related]
12. Dizocilpine (MK-801) and tetrodotoxin influence accumbal dopamine release evoked by intrapallidal morphine.
Anagnostakis Y; Kastellakis A; Spyraki C
Eur Neuropsychopharmacol; 1998 Feb; 8(1):47-53. PubMed ID: 9452940
[TBL] [Abstract][Full Text] [Related]
13. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
[TBL] [Abstract][Full Text] [Related]
14. Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists.
Bespalov A; Dravolina O; Belozertseva I; Adamcio B; Zvartau E
Behav Pharmacol; 2006 Jun; 17(4):295-302. PubMed ID: 16914947
[TBL] [Abstract][Full Text] [Related]
15. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Zadow B; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jan; 349(1):61-5. PubMed ID: 7908126
[TBL] [Abstract][Full Text] [Related]
16. Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity.
Del Arco A; Segovia G; Mora F
Psychopharmacology (Berl); 2008 Dec; 201(3):325-38. PubMed ID: 18751970
[TBL] [Abstract][Full Text] [Related]
17. Effects of competitive and non-competitive NMDA receptor antagonists on behavioral responses induced by 7-OH-DPAT and quinpirole in rats.
Dall'olio R; Rimondini R; Gandolfi O
Pharmacol Res; 1997 Sep; 36(3):203-9. PubMed ID: 9367665
[TBL] [Abstract][Full Text] [Related]
18. NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D(2/3) dopamine receptor stimulation in rats.
Biondo AM; Clements RL; Hayes DJ; Eshpeter B; Greenshaw AJ
Psychopharmacology (Berl); 2005 Apr; 179(1):189-97. PubMed ID: 15744543
[TBL] [Abstract][Full Text] [Related]
19. Activation of mesolimbic dopamine function by phencyclidine is enhanced by 5-HT(2C/2B) receptor antagonists: neurochemical and behavioural studies.
Hutson PH; Barton CL; Jay M; Blurton P; Burkamp F; Clarkson R; Bristow LJ
Neuropharmacology; 2000 Sep; 39(12):2318-28. PubMed ID: 10974315
[TBL] [Abstract][Full Text] [Related]
20. Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist.
Tzschentke TM; Schmidt WJ
Eur J Pharmacol; 1996 Jan; 295(2-3):137-46. PubMed ID: 8720577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
